• Home
• Services
• Bioconjugate Drug Development & Manufacturing
• Antibody-Protein/Peptide Conjugate

Antibody-Protein/Peptide Conjugate

CellMosaic® offers research and development services for biopharmaceutical companies developing antibody–protein or antibody–peptide conjugates as therapeutics. Antibodies contain natural amino acid functional groups suitable for conjugation—such as surface amines, carboxylic acids and phenolic groups —as well as unique disulfide bonds in the hinge region that can be selectively reduced for more targeted labeling.

At CellMosaic, we focus on developing conjugation processes that label antibodies at a single site or a small number of predictable sites while fully preserving antigen-binding affinity and specificity. For antibodies that can be engineered, we recommend cysteine mutagenesis to introduce a precise, well-defined labeling site. For antibodies that cannot be genetically modified, we identify chemically addressable sites for site-specific labeling. When true site-specific options are unavailable, we use controlled amine labeling combined with advanced purification methods to generate single-ratio conjugates or highly homogeneous multi-ratio conjugates.

Advantages of CellMosaic's antibody conjugation strategy:

• Flexibility to attach peptide or protein using mulitiple conjugation methods.
• Conjugation strategies can be easily adapted for different categories of compounds.
• Short development timelines for creating a customized bioconjugation strategy.

Examples:

1. Development of a single-labeled antibody-protein conjugate at CellMosaic® (shown below): antibody as a therapeutic agent while the protein acts as a delivery vehicle. 96% pure and free of any unreacted antibodies and proteins.